Hygiena, a global leader in rapid microbial detection, monitoring, and identification technology, introduced the InSite L. mono Glo Environmental Surface Screening Test. InSite L. mono Glo Environmental Surface Screening Test. InSite L. monoGlo is an easy-to-use, self-contained, environmental sampling and screening test for Listeria species and Listeria monocytogenes (L. mono).
The Pharma & Biopharma Outsourcing Association (PBOA), a trade group that represents Contract Manufacturing Organizations (CMOs) and other service providers in the bio/pharmaceutical sector, reports that many of its member companies are actively involved in helping their clients develop and produce treatments, vaccines, and diagnostics for COVID-19. PBOA’s members provide a wide array of services throughout the bio/pharma sector.
PCR Biosystems, the UK-based PCR experts, PCR Biosystems has the capacity to manufacture enough reagent daily for 4 million reactions – which is sufficient for millions of diagnostic tests
Apeiron Biologics AG has received regulatory approvals in Austria, Germany and Denmark to kickoff a Phase II clinical trial of APN01 to treat COVID-19.
The Ritedose Corporation, a contract development and manufacturing organisation (CDMO) with a focus on inhalation and ophthalmic products, has partnered
Swiss-based Lonza has launched the TheraPEAK SfAAV Medium, the first chemically defined, non-animal origin medium designed specifically for the production of Adeno Associated Virus (AAV) in Spodoptera Fuigiperda (Sf9) insect cells for gene therapy applications.
N4 Pharma will test a Covid-19 DNA plasmid if Nuvec, a novel delivery system for cancer treatments and vaccines, can be used as a delivery system by potential collaboration partners developing Covid-19 DNA or RNA vaccines.
You want to do what is excellent for your kids. You know about the importance of baby gates, car seats, and other ways to keep them secure. But, did you know that the most excellent way to protect your kids is to make sure they have all of their vaccinations?
ObsEva CEO Ernest Loumaye s said the instituting new measures to support the priorities of safety to manage through the COVID-19 pandemic.
Teva to donate potential COVID-19 Treatment, hydroxychloroquine sulfate tablets to hospitals nationwide
Teva said it will donate 6 Million tablets through wholesalers to hospitals by March 31, and more than 10 Million within a month, to meet the urgent demand for the medicine as an investigational target to treat COVID-19.